AM Pharma
3 known investors
AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
BiotechHealthtech
Investors · 3
In the news
Frequently asked questions
- What does AM Pharma do?
- AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
- Who are AM Pharma's investors?
- AM Pharma's investors include Andera Partners, Kurma Partners, Ysios Capital.